On a winning streak, Juno's top execs snag bonus pay

Juno CEO Hans Bishop

Juno Therapeutics ($JUNO) enjoyed one of the hottest IPOs in the biotech industry not so long ago, cashing in on its CAR-T rep. So it's no wonder that its top executives are enjoying some bonus pay these days.

As the Puget Sound Business Journal notes, Juno CEO Hans Bishop grabbed a $450,000 bonus for achieving 120% of his goals. That's slightly more than Bishop's base pay. CFO Steve Harr, meanwhile, gets a $200,000 bonus.

It's all lunch money compared to what their stock is worth these days.  Bishop was given 7.7 million shares in 2013 that vest over 4 years, another 3.1 million shares in early 2014 that also vest over 4 years and an option to buy 4 million shares at $1.59 per share. This morning the stock was trading at $45.18 a share.

That kind of success for the early-stage biotech certainly hasn't hurt its recruiting efforts. As the Business Journal notes, Juno has 50 open positions and has been bringing in researchers from Amgen ($AMGN)--which shut down its local R&D group--along with Seattle Genetics,  the University of Washington, Dendreon, Immune Design, ZymoGenetics, etc.

- here's the story fom the Business Journal

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.